INTRODUCTION: Oncotype DX® analyses the expression of 21 genes within tumour tissue to determine a Recurrence Score® (RS). RS is a marker of risk for distant recurrence in oestrogen receptor-positive early breast cancer, allowing patient-specific benefit of chemotherapy to be evaluated. Our aim was to determine whether the introduction of Oncotype DX led to a net reduction in chemotherapy use. METHODS: Consecutive patients that underwent Oncotype DX at Warwick Hospital were reviewed. Patients were anonymised and re-discussed at a multidisciplinary team meeting (MDM; without RS), and treatment recommendations were recorded. This was compared to the original MDM outcome (recommendations made with RS). Differences were analysed using Wilcoxon signed-rank test. RESULTS: 67 patients were identified. Proportions of high, intermediate and low risk were 28, 33 and 39% (n = 19/22/26), respectively. Without RS, 56 (84%) patients were recommended for chemotherapy and 3 were not. The remaining 8 patients were deemed borderline for requiring chemotherapy and referred for discussion with an oncologist. With availability of RS, 34 (50%) patients were recommended for chemotherapy, and 24 (43%) patients were spared chemotherapy (p < 0.0005). The net reduction in chemotherapy was 33%. CONCLUSION: There has been a significant reduction in chemotherapy usage in patients at Warwick since the introduction of Oncotype DX.
INTRODUCTION: Oncotype DX® analyses the expression of 21 genes within tumour tissue to determine a Recurrence Score® (RS). RS is a marker of risk for distant recurrence in oestrogen receptor-positive early breast cancer, allowing patient-specific benefit of chemotherapy to be evaluated. Our aim was to determine whether the introduction of Oncotype DX led to a net reduction in chemotherapy use. METHODS: Consecutive patients that underwent Oncotype DX at Warwick Hospital were reviewed. Patients were anonymised and re-discussed at a multidisciplinary team meeting (MDM; without RS), and treatment recommendations were recorded. This was compared to the original MDM outcome (recommendations made with RS). Differences were analysed using Wilcoxon signed-rank test. RESULTS: 67 patients were identified. Proportions of high, intermediate and low risk were 28, 33 and 39% (n = 19/22/26), respectively. Without RS, 56 (84%) patients were recommended for chemotherapy and 3 were not. The remaining 8 patients were deemed borderline for requiring chemotherapy and referred for discussion with an oncologist. With availability of RS, 34 (50%) patients were recommended for chemotherapy, and 24 (43%) patients were spared chemotherapy (p < 0.0005). The net reduction in chemotherapy was 33%. CONCLUSION: There has been a significant reduction in chemotherapy usage in patients at Warwick since the introduction of Oncotype DX.
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: Roland C Y Leung; Thomas C C Yau; Miranda C M Chan; Sharon W W Chan; Terence W C Chan; Yvonne Y Y Tsang; Ting Ting Wong; Calvin Chao; Carl Yoshizawa; Inda S Soong; Wing-Hong Kwan; Carol C H Kwok; Joyce S J Suen; Roger K C Ngan; Polly S Y Cheung Journal: Clin Breast Cancer Date: 2016-03-17 Impact factor: 3.225
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Ellen G Engelhardt; Alexandra J van den Broek; Sabine C Linn; Gordon C Wishart; Emiel J Th Rutgers; Anthonie O van de Velde; Vincent T H B M Smit; Adri C Voogd; Sabine Siesling; Mariël Brinkhuis; Caroline Seynaeve; Pieter J Westenend; Anne M Stiggelbout; Rob A E M Tollenaar; Flora E van Leeuwen; Laura J van 't Veer; Peter M Ravdin; Paul D P Pharaoh; Marjanka K Schmidt Journal: Eur J Cancer Date: 2017-04-14 Impact factor: 9.162
Authors: Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman B Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne Journal: Lancet Date: 2009-12-10 Impact factor: 79.321
Authors: Joan Albanell; Christer Svedman; Joseph Gligorov; Simon D H Holt; Gianfilippo Bertelli; Jens-Uwe Blohmer; Roman Rouzier; Ana Lluch; Wolfgang Eiermann Journal: Eur J Cancer Date: 2016-08-18 Impact factor: 9.162
Authors: Nienke A de Glas; Willemien van de Water; Ellen G Engelhardt; Esther Bastiaannet; Anton J M de Craen; Judith R Kroep; Hein Putter; Anne M Stiggelbout; Nir I Weijl; Cornelis J H van de Velde; Johanneke E A Portielje; Gerrit-Jan Liefers Journal: Lancet Oncol Date: 2014-05-13 Impact factor: 41.316
Authors: David Tiberi; Laura Masucci; Daniel Shedid; Isabelle Roy; Toni Vu; Erica Patocskai; André Robidoux; Philip Wong Journal: Cureus Date: 2017-03-17
Authors: Ulrike Nitz; Oleg Gluz; Matthias Christgen; Ronald E Kates; Michael Clemens; Wolfram Malter; Benno Nuding; Bahriye Aktas; Sherko Kuemmel; Toralf Reimer; Andrea Stefek; Fatemeh Lorenz-Salehi; Petra Krabisch; Marianne Just; Doris Augustin; Cornelia Liedtke; Calvin Chao; Steven Shak; Rachel Wuerstlein; Hans H Kreipe; Nadia Harbeck Journal: Breast Cancer Res Treat Date: 2017-06-29 Impact factor: 4.872
Authors: G C Wishart; C D Bajdik; E Dicks; E Provenzano; M K Schmidt; M Sherman; D C Greenberg; A R Green; K A Gelmon; V-M Kosma; J E Olson; M W Beckmann; R Winqvist; S S Cross; G Severi; D Huntsman; K Pylkäs; I Ellis; T O Nielsen; G Giles; C Blomqvist; P A Fasching; F J Couch; E Rakha; W D Foulkes; F M Blows; L R Bégin; L J van't Veer; M Southey; H Nevanlinna; A Mannermaa; A Cox; M Cheang; L Baglietto; C Caldas; M Garcia-Closas; P D P Pharoah Journal: Br J Cancer Date: 2012-07-31 Impact factor: 7.640
Authors: L M McSorley; M Tharmabala; F Al Rahbi; K McSorley; S Chew; D Evoy; J G Geraghty; R S Prichard; J Rothwell; D P McCartan; E W McDermott; M Keane; M J Kennedy; S O'Reilly; S J Millen; J P Crown; L M Smyth; C M Kelly; C M Quinn; J M Walshe Journal: Breast Cancer Res Treat Date: 2021-04-09 Impact factor: 4.872